ArticleACS omega2024
Development and Analytical Validation of a Surface-Enhanced Raman Scattering Paper Lateral Flow Immunoassay for Detection of the Ubiquitin C-Terminal Hydrolase-L1 Traumatic Brain Injury Biomarker.
Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gas-phase engineered gold-on-paper SERS substrates for quantitative thiabendazole sensing in real matrices.Mikrochimica acta · 2026Article
- Design, Implementation, and Advances in Indirect SERS Sensors for Biomedical and Human-Health-Related Analyte Detection.Sensors (Basel, Switzerland) · 2026Review
- Development of a monoclonal antibody-based time-resolved fluorescence immunochromatographic assay strip for rapid and quantitative determination of ubiquitin C-terminal hydrolase L1 in serum.Mikrochimica acta · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Paper lateral flow immunoassays combined with surface-enhanced Raman scattering (SERS) technology have gained increasing attention due to their high sensitivity characteristics resulting from the amplified SERS signals of the plasmon-enhanced optical probes. In contrast to conventional colorimetric lateral flow strips, SERS paper lateral flow strips (SERS-PLFSs) are currently not commercially available for widespread use. Analytical validation is the key step for commercialization. In this work, we have developed a PLFS with a hierarchical SERS probe (gold-silver nanoparticle@Raman reporter@silica) for detection of the US Food and Drug Administration (FDA)-approved traumatic brain injury (TBI) protein biomarker, ubiquitin C-terminal hydrolase-L1 (UCH-L1), in blood plasma samples. Analytical validation has been performed on this SERS-PLFS in terms of the limit of detection (LOD), limit of quantification (LOQ), accuracy, precision, selectivity, and stability. The SERS-PLFS exhibits a reportable range of 0.2-100 ng/mL with a LOD of 0.08 ng/mL toward measurement of UCH-L1 in blood plasma. The SERS-PLFS has been applied to clinical TBI samples. The test results were compared with those from enzyme-linked immunosorbent assay (ELISA), demonstrating a strong correlation between the two analytical methods. This study has important implications in the commercialization of SERS-PLFSs for rapid TBI detection in clinical practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.